The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified fusion polypeptides.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Genetically modified fusion polypeptides is a key innovation area in drug development
A recombinant fusion protein is made by genetically engineering a fusion gene. Fusion genes may occur naturally in the body by the transfer of DNA between chromosomes or can be made in the laboratory by combining genes or parts of genes from the same or different organisms to treat diseases.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 190+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of genetically modified fusion polypeptides.
Key players in genetically modified fusion polypeptides – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to genetically modified fusion polypeptides
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Bristol-Myers Squibb||620||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||379||Unlock company profile|
|Cellectis||326||Unlock company profile|
|Gilead Sciences||301||Unlock company profile|
|bluebird bio||225||Unlock company profile|
|Autolus||221||Unlock company profile|
|Eureka Therapeutics||208||Unlock company profile|
|City of Hope||201||Unlock company profile|
|Fred Hutchinson Cancer Research Center||183||Unlock company profile|
|Miltenyi Biotec||153||Unlock company profile|
|CARsgen Therapeutics||139||Unlock company profile|
|CRISPR Therapeutics||121||Unlock company profile|
|Seattle Children's Hospital||120||Unlock company profile|
|TCR2 Therapeutics||115||Unlock company profile|
|ImmunityBio||109||Unlock company profile|
|Pfizer||102||Unlock company profile|
|Aleta Biotherapeutics||100||Unlock company profile|
|Alpine Immune Sciences||86||Unlock company profile|
|Precision Biosciences||81||Unlock company profile|
|Amgen||77||Unlock company profile|
|Innovative Cellular Therapeutics||76||Unlock company profile|
|Massachusetts General Hospital||65||Unlock company profile|
|Nanjing Legend Biotech||64||Unlock company profile|
|Fate Therapeutics||62||Unlock company profile|
|BioNTech||60||Unlock company profile|
|iCell Gene Therapeutics||59||Unlock company profile|
|Allogene Therapeutics||56||Unlock company profile|
|Regeneron Pharmaceuticals||55||Unlock company profile|
|United States Of America||54||Unlock company profile|
|Sangamo Therapeutics||53||Unlock company profile|
|PT Soho Global Health Tbk||50||Unlock company profile|
|CytoImmune Therapeutics||48||Unlock company profile|
|Johnson & Johnson||44||Unlock company profile|
|Precigen||44||Unlock company profile|
|Genscript Biotech||42||Unlock company profile|
|Gracell Biotechnologies||41||Unlock company profile|
|Editas Medicine||41||Unlock company profile|
|Io Therapeutics||41||Unlock company profile|
|Obsidian Therapeutics||39||Unlock company profile|
|Adicet Bio||35||Unlock company profile|
|Poseida Therapeutics||35||Unlock company profile|
|BioAtla||35||Unlock company profile|
|Puretech Health||34||Unlock company profile|
|Minerva Biotechnologies||34||Unlock company profile|
|Ministry of Trade and Industry, Singapore||33||Unlock company profile|
|IONTAS||33||Unlock company profile|
|Nkarta||32||Unlock company profile|
|Bellicum Pharmaceuticals||31||Unlock company profile|
|CERo Therapeutics||31||Unlock company profile|
|TRON gGmbH||31||Unlock company profile|
Source: GlobalData Patent Analytics
Bristol-Myers Squibb (BMS) is one of the leading patent filers for genetically modified fusion polypeptides. BMS is a specialty biopharmaceutical company that is engaged in discovery, development, licensing, manufacturing, marketing, distribution, and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic indications.
In terms of application diversity, Jiangsu Hengrui Medicine is the top company, followed by Avectas and Fate Therapeutics. By means of geographic reach, Genscript Biotech holds the top position, while Juventas Cell Therapy and Curocell stand in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.